In the last trading session, 1.27 million shares of the Dyne Therapeutics Inc (NASDAQ:DYN) were traded, and its beta was 1.09. Most recently the company’s share price was $29.34, and it changed around $0.95 or 3.35% from the last close, which brings the market valuation of the company to $2.80B. DYN currently trades at a discount to its 52-week high of $47.45, offering almost -61.72% off that amount. The share price’s 52-week low was $9.76, which indicates that the current value has risen by an impressive 66.73% since then. We note from Dyne Therapeutics Inc’s average daily trading volume that its 10-day average is 1.3 million shares, with the 3-month average coming to 1.28 million.
Dyne Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.20. If we narrow it down even further, the data shows that 0 out of 13 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 4 recommended DYN as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. Dyne Therapeutics Inc is expected to report earnings per share of -0.86 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Dyne Therapeutics Inc (NASDAQ:DYN) trade information
Instantly DYN has showed a green trend with a performance of 3.35% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 35.68 on recent trading dayincreased the stock’s daily price by 17.77%. The company’s shares are currently up 120.60% year-to-date, but still up 4.30% over the last five days. On the other hand, Dyne Therapeutics Inc (NASDAQ:DYN) is -16.74% down in the 30-day period. We can see from the shorts that 9.94 million shares have been sold at a short interest cover period of 12.11 day(s).
The consensus price target as assigned by Wall Street analysts is $45, which translates to bulls needing to increase their stock price by 34.8% from its current value. Analyst projections state that DYN is forecast to be at a low of $18 and a high of $55.
Dyne Therapeutics Inc (DYN) estimates and forecasts
Dyne Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -17.07 percent over the past six months and at a 14.18% annual growth rate that is well below the industry average of 15.60%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 21.38% in revenue this quarter, and will report an increase of 10.19% in the next quarter.
Forecasts for the next quarter put sales growth at �.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -106.26%.
DYN Dividends
Dyne Therapeutics Inc’s next quarterly earnings report is expected to be released in December.
Dyne Therapeutics Inc (NASDAQ:DYN)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.49% of Dyne Therapeutics Inc shares, and 112.41% of them are in the hands of institutional investors. The stock currently has a share float of 112.96%. Dyne Therapeutics Inc stock is held by 290.0 institutions, with ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC being the largest institutional investor. By 2024-06-30, it held 9.8961% of the shares, which is about 8.02 million shares worth $283.03 million.
FCPM III SERVICES B.V., with 9.6804% or 7.85 million shares worth $276.86 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
